ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Abstract P1-03-09: Pegylated recombinant human hyaluronidase PH20 (PEGPH20) enhances efficacy of eribulin mesylate (HALAVEN®) in triple negative breast cancer xenografts
Mapping Intimacies
◽
10.1158/1538-7445.sabcs15-p1-03-09
◽
2016
◽
Author(s):
JD Bahn
◽
C DesJardins
◽
KB Condon
◽
A Fathallah
◽
S Zimmerman
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Eribulin Mesylate
◽
Recombinant Human Hyaluronidase
◽
Breast Cancer Xenografts
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.735554384.793559073
◽
2019
◽
Author(s):
Ahmad Awada
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Eribulin Mesylate
◽
Phase 1B
Download Full-text
Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
Cancer Medicine
◽
10.1002/cam4.1705
◽
2018
◽
Vol 7
(9)
◽
pp. 4371-4378
◽
Cited By ~ 5
Author(s):
Sarah S. Mougalian
◽
Ronda Copher
◽
Jonathan K. Kish
◽
Lindsay McAllister
◽
Zhixiao Wang
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Clinical Benefit
◽
Triple Negative
◽
Long Term Outcomes
◽
Eribulin Mesylate
◽
Community Oncology
◽
The Us
Download Full-text
Abstract C166: Combining an anti-Trop-2 antibody-SN-38 conjugate (sacituzumab govitecan) with microtubule inhibitors (paclitaxel and eribulin mesylate) or PARP inhibitor (olaparib) significantly improves therapeutic outcome in experimental triple-negative breast cancer (TNBC)
10.1158/1535-7163.targ-15-c166
◽
2015
◽
Cited By ~ 1
Author(s):
Thomas M. Cardillo
◽
Serengulam V. Govindan
◽
Maria Zalath
◽
Roberto Arrojo
◽
Robert M. Sharkey
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Parp Inhibitor
◽
Therapeutic Outcome
◽
Eribulin Mesylate
◽
Microtubule Inhibitors
Download Full-text
Abstract 2835: Voruciclib, a clinical stage oral CDK inhibitor, sensitizes triple negative breast cancer xenografts to proteasome inhibition
10.1158/1538-7445.am2016-2835
◽
2016
◽
Cited By ~ 1
Author(s):
Joyoti Dey
◽
Joseph Casalini
◽
Sally Ditzler
◽
Matt Biery
◽
Angela Merrell
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Clinical Stage
◽
Proteasome Inhibition
◽
Cdk Inhibitor
◽
Breast Cancer Xenografts
Download Full-text
Abstract 2411: Evolution during propagation and treatment of patient-derived triple negative breast cancer xenografts
10.1158/1538-7445.am2016-2411
◽
2016
◽
Author(s):
Hyunsoo Kim
◽
Pooja Kumar
◽
Francesca Menghi
◽
Joshy George
◽
Guru Ananda
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Breast Cancer Xenografts
Download Full-text
Abstract P6-02-04: Eribulin mesylate promotes a mesenchymal-epithelial transition (MET) and effectively radio-sensitizes triple negative breast cancer cells
10.1158/1538-7445.sabcs14-p6-02-04
◽
2015
◽
Author(s):
Eileen P Connolly
◽
Youping Sun
◽
Tom K Hei
Keyword(s):
Breast Cancer
◽
Cancer Cells
◽
Triple Negative Breast Cancer
◽
Breast Cancer Cells
◽
Triple Negative
◽
Eribulin Mesylate
◽
Mesenchymal Epithelial Transition
Download Full-text
Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
10.1158/1538-7445.sabcs17-pd6-13
◽
2018
◽
Cited By ~ 11
Author(s):
SM Tolaney
◽
K Kalinsky
◽
V Kaklamani
◽
C Savulsky
◽
M Olivo
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Eribulin Mesylate
◽
Phase 1B
Download Full-text
24 Androgen receptor (AR) expression in triple negative breast cancer (TNBC): results from a phase II neoadjuvant trial with carboplatin and eribulin mesylate in TNBC patients
European Journal of Cancer
◽
10.1016/s0959-8049(14)70150-9
◽
2014
◽
Vol 50
◽
pp. 14
Author(s):
K. Siziopikou
◽
V. Parini
◽
V. Kaklamani
Keyword(s):
Breast Cancer
◽
Androgen Receptor
◽
Phase Ii
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Eribulin Mesylate
Download Full-text
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
PLoS ONE
◽
10.1371/journal.pone.0220644
◽
2019
◽
Vol 14
(8)
◽
pp. e0220644
◽
Cited By ~ 2
Author(s):
Serena Di Cosimo
◽
Nicla La Verde
◽
Anna Moretti
◽
Marina Elena Cazzaniga
◽
Daniele Generali
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Eribulin Mesylate
Download Full-text
Abstract B25: Using species-specific RNAseq reveals stromal reprogramming in triple-negative breast cancer xenografts
10.1158/1538-7445.tim2013-b25
◽
2013
◽
Author(s):
Casey A. Frankenberger
◽
Russell O. Bainer
◽
Jyotsana Menon
◽
Claudia Chavarria
◽
Katelyn Michelini
◽
...
Keyword(s):
Breast Cancer
◽
Triple Negative Breast Cancer
◽
Triple Negative
◽
Species Specific
◽
Breast Cancer Xenografts
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close